AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06358027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: The patients included in the study underwent lung imaging with lung ultrasound score twice, in the preoperative preparation room and in the postoperative recovery unit.Both lungs were determined as anterior and posterior axillary lines as anatomical markers and divided into a total of 12 regions, 4 in the anterior thoracic wall, 4 in the lateral wall, and 4 in the posterior region. In our study, we will use the modified LUS scoring, which has been shown to be more sensitive in the diagnosis of postoperative atelectasis in the recovery unit, based on existing literature reviews. The degree of the atelectasis will be determined according to do modified lung ultrasound score. Lung ultrasound score imaging of all patients was performed by the same anesthesiologist.
Study NCT05917964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-168 tablet
Description: LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
Study NCT04269785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon ablation
Description: Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using cryoballoon catheter (cold therapy)
Study NCT04269785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using radiofrequency catheter (heat therapy)
Study NCT05758415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
Study NCT05169944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Anti-cancer therapeutic agent targeting the CD47-signal receptor protein-alpha (SIRP-alpha) axis
Study NCT05389423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 0.4 mg/m2/day administered by CIVI on days 1 to 4
Study NCT05389423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/m2/day administered orally on days 1 to 5
Study NCT05389423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 10 mg/m2/day administered by CIVI on days 1 to 4
Study NCT05389423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg/m2/day administered by CIVI on days 1 to 4
Study NCT05389423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.
Study NCT05389423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 administered IV on day 5
Study NCT05389423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered IV on day 1 (only for CD20+ tumors)
Study NCT05750173 — intervention group
Intervention type: OTHER
Intervention: Streamlining of the pre-procedural patient pathway
Description: Pre-TAVI ICA is associated with procedural risk, radiation, costs and requires hospitalization (2d).~Show that CTA is a viable alternative to rule out ≥50% left main coronary artery (LM) / prox. left anterior descending artery (LAD) stenosis.~An implementation of a standardized patient pathway which is reproducible, will help to streamline the pre-procedural workup of patients without compromising patient safety.
Study NCT05267106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: 13.5mg tablet taken every morning (unless otherwise directed) for 2 weeks and then 1 week off.
Study NCT05475548 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: powerscope
Description: The PowerScope is the latest innovation in the treatment of Class II malocclusion which is a direct derivative of the Herbst Type II appliance. Dr. Andy Hayes worked in conjunction with American Orthodontics to develop PowerScope in 2016. This appliance supports intermaxillary wire-to-wire installation via a nut and hexagonal screw. A ball and socket joint is used to maximize lateral movement while improving patient comfort. The appliance is made up of a telescopic mechanism made up of an inner shaft/push rod, middle and outer tubing, and a spacer between the middle and outer tubing. A nickel-titanium (NiTi) spring provides a constant 260 g force. According to the present knowledge no studies regarding treatment outcomes of comprehensive fixed appliance treatment combined with the PowerScope in Class ΙII patients have been reported
Study NCT05892731 — intervention group
Intervention type: OTHER
Intervention: with depression
Description: age-related hearing loss with depression
Study NCT05892731 — intervention group
Intervention type: OTHER
Intervention: without depression
Description: age-related hearing loss without depression
Study NCT05178953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate 220 mg Capsules
Description: Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months
Study NCT06403436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT125-802
Description: TT125-802 administered orally
Study NCT05178953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months
Study NCT04770337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STARSTIM device
Description: Cathodal Transcranial Direct Current Stimulation (tDCS). Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
Study NCT04770337 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Intervention which uses enough currents to generate a sensory feedback similar to that of active stimulation via electrodes on the scalp
Study NCT04362579 — intervention group
Intervention type: DEVICE
Intervention: wearable vital signs sensor
Description: vital signs monitoring during maternal non-stress testing or in the home setting
Study NCT05139368 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study NCT02588846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'
Description: This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.
Study NCT05895279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Watch MiCaP Research Digest video
Study NCT05895279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Media Intervention
Description: Watch alternate video
Study NCT05895279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete survey
Study NCT05895279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study NCT06294925 — intervention group
Intervention type: DRUG
Intervention: Etrasimod
Description: As provided in real world practice
Study NCT04997265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity anticoagulation
Description: Participants assigned to the low intensity anticoagulation strategy will receive anticoagulation at doses used for DVT prophylaxis in critically ill patients. The choice of agent (e.g. heparin or enoxaparin) and specific dosing will be at the discretion of the treating clinicians and will be prospectively recorded.
Study NCT04997265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Anticoagulation
Description: Patients assigned to the moderate intensity anticoagulation strategy will receive anticoagulation targeting a PTT goal of 40-60 seconds or anti-Xa level of 0.2 to 0.3 IU/mL. Choice of anticoagulant and monitoring strategy (PTT or anti-Xa level) will be at the discretion of the treating clinicians and will be prospectively recorded. Anticoagulant drips will be titrated according to institutional protocols. For patients who survive to decannulation, the infusion will be stopped one hour prior to decannulation.~This approach to anticoagulation reflects the current approach for patients receiving V-V ECMO at Vanderbilt University Medical Center and is similar to protocols widely adopted for patients receiving V-V ECMO at other centers.
Study NCT05623345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study NCT05623345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to izokibep
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study NCT05081583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hcl 1Mg/Ml Inj
Description: 0.5 mL of an intravenous solution (1 mg/mL) will be administered.
Study NCT05081583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goldenseal (Hydrastis canadensis)
Description: Goldenseal (Solaray; Lot #1020199) is supplied as dried root powder in vegetable capsules, each containing 550 mg of herbal content. Goldenseal capsules will be administered with 240 mL of water.
Study NCT05349682 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dynamic contrast enhanced MRI
Description: An MRI study of the knee will be done to check the degree of osteoarthritis and blood flow to the affected knee. This scan will take about 1-2 hour(s).
Study NCT05349682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: geniculate artery embolization
Description: The physician will perform a diagnostic angiography, where they will take pictures of vessels near the knee that will be treated. Once the artery to be treated is identified, the doctor will guide a thin wire called a microwire, and a plastic tube called a microcatheter to the targeted artery, and more pictures of vessels at the knee will be taken. This picture will be used to see if there are any abnormal vessels at the knee, such as abnormal blood flow, abnormal vessel connections (between the veins and arteries), or new blood vessel growth. Once the targeted artery at the knee is confirmed, the doctor will inject enough particle embolic (Embozene) to slow or stop the blood flow in the geniculate artery. Once all vessels are treated, a final angiogram (pictures of blood vessels) will be performed to ensure that the blood flow has slowed.
Study NCT05868577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (CSI) with local anesthetic (LA)
Description: The PI will then administer the injection using an infracalcaneal needle peppering
Study NCT06490094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR)
Description: The 8-week IBSR program is a clinical intervention based on The Work method, developed by Byron Katie and run in the US and Europe for 35 years. The IBSR intervention will involve weekly group meetings (3 hours/meeting) throughout 8 weeks. Home practice between sessions will be supported by facilitator assistants (1-hour session per week). All sessions will be standardized according to the IBSR certification program guidelines and will be assessed to maintain consistency in the program, as in previous studies. .
Study NCT05703542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL701
Description: Tablet, taken Orally
Study NCT04848909 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: Stereotactic body or external-beam radiation therapy (SBRT) is a method of delivery of radiation in precision manner to the prostate bed in this study. The SBRT dose prescription will be 3000 cGy in 5 fractions to the prostate bed and 2500 cGy in 5 fractions to the pelvic nodes if elective nodal irradiation (ENI) is used, delivered every other business day.
Study NCT05388006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT05388006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT05388006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT05417997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kunamin®
Description: Grape juice, seed, stem and rice extracts supplement containing KH good healthy cells (proteins)
Study NCT05417997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Favipiravir
Description: Antiviral medication used to treat influenza
Study NCT05417997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Antiviral medication used to treat influenza
Study NCT05417997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin
Description: Anticoagulant medication
Study NCT05417997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Anticoagulant medication
Study NCT05417997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lansoprazole
Description: Treat stomach ulcers, a damaged esophagus, gastroesophageal reflux disease (GERD), and high levels of stomach acid.
Study NCT05417997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Treat stomach ulcers, a damaged esophagus, gastroesophageal reflux disease (GERD), and high levels of stomach acid.
Study NCT05417997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: Analgesic to treat minor aches and pains, and fever reducer.
Study NCT05417997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Analgesic to treat minor aches and pains, and fever reducer.
Study NCT06440278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Health and Depression (BA-HD)
Description: BA-HD includes 8 - 10 sessions delivered over 10-12 weeks. Sessions use behavioral activation techniques to connect patient core values with goal-setting targeting activities that improve mood, alongside personalized adjustments to cardiovascular health behaviors (i.e., tobacco cessation, medication adherence, physical activity, diet, and sleep). Educational materials and commercially available tools like activity trackers, pillboxes, and portion control aids will accompany the goal-setting process to facilitate behavior change.
Study NCT06440278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients will receive depression and heart disease education, as well as a list of local mental health resources.
Study NCT04620941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: reticulocyte/hemoglobin (Ret-He) ratio
Description: Ret-He values will be studied on the day (1st day), 4th and 7th days of the diagnosis of ventilator-associated pneumonia in patients hospitalized in the intensive care unit.
Study NCT06383949 — intervention group
Intervention type: DEVICE
Intervention: Synergy Cervical Disc system
Description: motion preservation disc
Study NCT06632236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be supplied in single-use 350 mg injectable solution, provided as a 7 ml per glass vial (50mg/ml), intended for IV infusion.
Study NCT05759156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid injection
Description: The intervention consists of administration of 1gm of Tranexamic acid (TXA) intravenously or 10-mls of placebo (normal saline) intravenously, slowly over 30-60 sec, within 3 mins of the delivery of baby.
Study NCT05759156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: The intervention consists of administration of 1gm of Tranexamic acid (TXA) intravenously or 10-mls of placebo (normal saline) intravenously, slowly over 30-60 sec, within 3 mins of the delivery of baby.
Study NCT06361355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Post-change CMAB807
Description: for subcutaneous injection only
Study NCT06361355 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolia
Description: for subcutaneous injection only
Study NCT05260203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RITA (App)
Description: The RITA Remote Intelligence for Therapeutic Adherence application was designed, on the doctor's side, as a support for the management of the onco-hematological patient and, on the patient's side, as a first aid tool for the management of the most common problems, as well as an efficient and non-invasive means of communication with the doctor. The system also allows the caregiver and general practitioner to be included in the communication group.~The added value of the app consists in improving the relationship between the patient and the doctor, creating an effective communication channel, increasing the safety the patient has when facing his difficult path, reducing the number of visits to the facility and, in general, making those visits more efficient, thus creating savings both in terms of time and resources.
Study NCT06248645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxygen
Description: High-flow oxygen (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
Study NCT06248645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: High-flow medical air (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
Study NCT05417997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ceftriaxone/ Clarithromycin
Description: Inhibits the production of pneumolysin
Study NCT05417997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone/ Clarithromycin
Description: Inhibits the production of pneumolysin
Study NCT06220526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
Description: Transbronchial biopsy with Menghini-type or Franseen type Needle
Study NCT06220526 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
Description: Transbronchial biopsy with Menghini-type or Franseen type Needle
Study NCT02386007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-3101_150mg
Study NCT02386007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-3101_300mg
Study NCT02386007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-3101_600mg
Study NCT02386007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05434091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07291177
Description: PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
Study NCT05434091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
Study NCT06292364 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: immediate orthodontic retainer delivery
Description: post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
Study NCT06292364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed orthodontic retainer delivery
Description: post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
Study NCT04712734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: oral tablet, long-acting injection
Study NCT05417997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Treat inflammation, severe allergies, flares of chronic illnesses
Study NCT05417997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Treat inflammation, severe allergies, flares of chronic illnesses